A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABAB) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerability of chlordiazepoxide with baclofen, the present study was taken up. The objective of this study was to compare efficacy and tolerability of baclofen with chlordiazepoxide in uncomplicated AWS. METHODS: Sixty subjects with uncomplicated AWS were randomized into two groups of 30 each, to receive baclofen (30 mg) or chlordiazepoxide (75 mg) in decremented fixed dose regime for 9 days. Clinical efficacy was assessed by Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWA-Ar) and tolerability by the nature and severity of adverse events. Lorazepam was used as rescue medication. Secondary efficacy parameters were Clinical Global Impression scores, symptom-free days, and subject satisfaction as assessed by visual analog scale. This study was registered with Clinical Trial Registry-India (CTRI/2013/04/003588), also subsequently registered with WHO's ICTRP clinical trial portal. RESULTS: Both baclofen and chlordiazepoxide showed a consistent reduction in the total CIWA-Ar scores. However, chlordiazepoxide showed a faster and a more effective control of anxiety and agitation requiring lesser lorazepam supplementation, and also showed a better subject satisfaction compared to baclofen. Both the drugs showed good tolerability with mild self-limiting adverse events. CONCLUSION: The present study demonstrates that baclofen is not as good as chlordiazepoxide in the treatment of uncomplicated AWS. However, baclofen might be considered as an alternative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Room, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625 · cited 1×
“It accounts for about 4% of all deaths worldwide [1].”
BackgroundThe diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 2×
“[7,12] The expected percentage response in baclofen Group was taken as 85% and for chlordiazepoxide Group as 95% and the noninferiority criteria is set to be an absolute value of 10%.”
MethodBaclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam
Addolorato, G., Leggio, L., Abenavoli, L., Agabio, R., Caputo, F., Capristo, E., Colombo, G., Gessa, G. L., & Gasbarrini, G. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.042 · Cited by 203
Cited by
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Baclofen and the Alcohol Withdrawal Syndrome—A Short Review
Cooney, G., Heydtmann, M., & Smith, I. D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00773 · Cited by 24
“Frontiers in Psychiatry | www.frontiersin.org 3 January 2019 | Volume 9 | Article 773 The Indian study by Reddy and Girish (24, 25) sought to compare baclofen with chlordiazepoxide in the context of alcohol detoxification with regards to efficacy and tolerability in uncomplicated alcohol withdrawal.”
BackgroundCrunelle, C. L., Jegham, S., Vanderbruggen, N., & Matthys, F. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad050 · Cited by 5
Metadata
- Authors
- Girish, K., Vikram Reddy, K., Pandit, L. V., Pundarikaksha, H. P., Vijendra, R., Vasundara, K., Manjunatha, R., Nagraj, M., & Shruthi, R.
- Venue
- Biomedical Journal
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 39
- Issue
- 1
- Pages
- 72-80
- ISSN
- 2319-4170 (ISSN-L)
- OpenAlex
- W2320539563
- Cited by
- 40
- References
- 3
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.